KKR & Co. Inc. (KKR)
After hours:
| Previous close | 95.28 |
| Open | 93.88 |
| Bid | 93.20 x 900 |
| Ask | 93.40 x 1100 |
| Day's range | 92.97 - 95.21 |
| 52-week range | 47.79 - 103.48 |
| Volume | |
| Avg. volume | 3,677,009 |
| Market cap | 82.783B |
| Beta (5Y monthly) | 1.62 |
| PE ratio (TTM) | 22.76 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.66 (0.69%) |
| Ex-dividend date | 15 Feb 2024 |
| 1y target est | N/A |
- Business Wire
KKR’s Henry McVey Says Insurance CIOs Plan to Increase Allocations to Non-Traditional Assets
NEW YORK, April 30, 2024--KKR, a leading global investment firm, today released "No Turning Back," a new Insights piece by Henry McVey, CIO of KKR’s Balance Sheet and Head of Global Macro and Asset Allocation (GMAA).
- Business Wire
KKR to Acquire $1.64 Billion Student Housing Portfolio from BREIT
NEW YORK, April 25, 2024--KKR and Blackstone Real Estate Income Trust, Inc. ("BREIT") today announced a definitive agreement for funds managed by KKR to acquire a portfolio of 19 purpose-built student housing properties from BREIT for approximately $1.64 billion.
- Business Wire
KKR and Impilo Announce Strategic Partnership Together With Management in Rare Disease Platform Immedica Pharma
STOCKHOLM & LONDON, April 23, 2024--Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions.
